Biosyngen's BRG01 Receives FDA Approval for Phase II Clinical Trial
Details : BRG01 is an CAR-T cell therapy, engineered to target the EBV antigen, which is being investigated in patients with EBV-expressed nasopharyngeal carcinoma tumor cells.
Product Name : BRG01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 08, 2024
Lead Product(s) : AUM001,Irinotecan Hydrochloride,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUM001 is a mRNA translation inhibitor that targets MNK 1/2 and the chokepoint of multiple pro-oncogenic signalling pathways, being investigated for the treatment of metastatic colorectal cancer.
Product Name : AUM001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2023
Lead Product(s) : AUM001,Irinotecan Hydrochloride,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL). The CD30.CAR-T cell therapy was demonstrated to be well tolerated with no unexpected safety signals...
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUM001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AUM001 is highly selective translation inhibitor. In vitro, it was observed to selectively inhibit MAPK – interacting protein kinase (MNK) types 1/2 and is expected to thereby block phosphorylation of eIF4E, and in turn, interfere with CAP mediated RNA...
Product Name : AUM001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2022
Lead Product(s) : AUM001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Polaris Partners
Deal Size : $126.0 million
Deal Type : Series A Financing
Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners
Details : Tessa plans to use the proceeds from the financing to advance the ongoing clinical development of the company’s autologous CD30-CAR-T therapy (TT11) and allogeneic CD30.CAR EBVST therapy (TT11X) programs.
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Polaris Partners
Deal Size : $126.0 million
Deal Type : Series A Financing
Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TT11 – is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma.
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 13, 2022
Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AUM001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This collaboration with MSD marks a major milestone and enables the joint clinical development of AUM001 in combination with KEYTRUDA. As a monotherapy, AUM001 demonstrated encouraging safety, tolerability and target engagement in two Phase 1 studies.
Product Name : AUM001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : AUM001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : AI-based Stain-free imaging technology will be utilized to analyze and quantify collagen-associated parameters as part of Galecto's Phase 2a trial for its oral LOXL2 inhibitor GB2064 in myelofibrosis.
Product Name : PAT-1251
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 20, 2021
Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Details : The PRIME designation was granted to TT11 by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center.
Product Name : TT11
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 18, 2021
Lead Product(s) : TT11,Bendamustine Hydrochloride,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tessa gets RMAT designation for new CAR-T
Details : The designation is based on the data of two independent Phase I/II trials, which show promising efficacy and strong safety profile of the therapy in Hodgkin lymphoma patients.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 27, 2020